CNTA - Centessa Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.019B

Cash

230.2M

Avg Qtr Burn

-37.45M

Short % of Float

2.03%

Insider Ownership

1.84%

Institutional Own.

77.91%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
SerpinPC Details Hemophilia	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LB101 (PD-L1xCD47 LockBody) Details Cutaneous squamous cell carcinoma, Cancer, Solid tumor/s	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORX750 Details Narcolepsy, Sleep-wake disorder	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imgatuzumab Details Solid tumor/s, Cancer, Cutaneous squamous cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lixivaptan Details Kidney disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.